Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

861 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
HIV disease progression in seroconvertors from the CAPRISA 004 tenofovir gel pre-exposure prophylaxis trial.
Garrett NJ, Werner L, Naicker N, Naranbhai V, Sibeko S, Samsunder N, Gray C, Williamson C, Morris L, Abdool-Karim Q, Abdool-Karim SS. Garrett NJ, et al. Among authors: werner l. J Acquir Immune Defic Syndr. 2015 Jan 1;68(1):55-61. doi: 10.1097/QAI.0000000000000367. J Acquir Immune Defic Syndr. 2015. PMID: 25247433 Free PMC article. Clinical Trial.
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D; CAPRISA 004 Trial Group. Abdool Karim Q, et al. Science. 2010 Sep 3;329(5996):1168-74. doi: 10.1126/science.1193748. Epub 2010 Jul 19. Science. 2010. PMID: 20643915 Free PMC article. Clinical Trial.
Preservation HIV-1-specific IFNγ+ CD4+ T-cell responses in breakthrough infections after exposure to tenofovir gel in the CAPRISA 004 microbicide trial.
Mureithi MW, Poole D, Naranbhai V, Reddy S, Mkhwanazi NP, Sibeko S, Werner L, Abdool Karim Q, Abdool Karim S, Ndung'u T, Altfeld M; CAPRISA004 Trial Group. Mureithi MW, et al. Among authors: werner l. J Acquir Immune Defic Syndr. 2012 Jun 1;60(2):124-7. doi: 10.1097/QAI.0b013e31824f53a9. J Acquir Immune Defic Syndr. 2012. PMID: 22362152 Free PMC article.
CAPRISA 004 tenofovir microbicide trial: no impact of tenofovir gel on the HIV transmission bottleneck.
Valley-Omar Z, Sibeko S, Anderson J, Goodier S, Werner L, Arney L, Naranbhai V, Treurnicht F, Abrahams MR, Bandawe G, Swanstrom R, Karim QA, Karim SS, Williamson C. Valley-Omar Z, et al. Among authors: werner l. J Infect Dis. 2012 Jul 1;206(1):35-40. doi: 10.1093/infdis/jis305. Epub 2012 May 2. J Infect Dis. 2012. PMID: 22551813 Free PMC article. Clinical Trial.
Sensitive tenofovir resistance screening of HIV-1 from the genital and blood compartments of women with breakthrough infections in the CAPRISA 004 tenofovir gel trial.
Wei X, Hunt G, Abdool Karim SS, Naranbhai V, Sibeko S, Abdool Karim Q, Li JF, Kashuba AD, Werner L, Passmore JA, Morris L, Heneine W, Johnson JA. Wei X, et al. Among authors: werner l. J Infect Dis. 2014 Jun 15;209(12):1916-20. doi: 10.1093/infdis/jiu026. Epub 2014 Jan 16. J Infect Dis. 2014. PMID: 24436453 Free PMC article. Clinical Trial.
The preventive misconception: experiences from CAPRISA 004.
Dellar RC, Abdool Karim Q, Mansoor LE, Grobler A, Humphries H, Werner L, Ntombela F, Luthuli L, Abdool Karim SS. Dellar RC, et al. Among authors: werner l. AIDS Behav. 2014 Sep;18(9):1746-52. doi: 10.1007/s10461-014-0771-6. AIDS Behav. 2014. PMID: 24715227
Rapid disease progression in HIV-1 subtype C-infected South African women.
Mlisana K, Werner L, Garrett NJ, McKinnon LR, van Loggerenberg F, Passmore JA, Gray CM, Morris L, Williamson C, Abdool Karim SS; Centre for the AIDS Programme of Research in South Africa (CAPRISA) 002 Study Team. Mlisana K, et al. Among authors: werner l. Clin Infect Dis. 2014 Nov 1;59(9):1322-31. doi: 10.1093/cid/ciu573. Epub 2014 Jul 17. Clin Infect Dis. 2014. PMID: 25038116 Free PMC article.
Genital Tenofovir Concentrations Correlate With Protection Against HIV Infection in the CAPRISA 004 Trial: Importance of Adherence for Microbicide Effectiveness.
Kashuba AD, Gengiah TN, Werner L, Yang KH, White NR, Karim QA, Abdool Karim SS. Kashuba AD, et al. Among authors: werner l. J Acquir Immune Defic Syndr. 2015 Jul 1;69(3):264-9. doi: 10.1097/QAI.0000000000000607. J Acquir Immune Defic Syndr. 2015. PMID: 26181703 Free PMC article. Clinical Trial.
Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection.
Abdool Karim SS, Abdool Karim Q, Kharsany AB, Baxter C, Grobler AC, Werner L, Kashuba A, Mansoor LE, Samsunder N, Mindel A, Gengiah TN; CAPRISA 004 Trial Group. Abdool Karim SS, et al. Among authors: werner l. N Engl J Med. 2015 Aug 6;373(6):530-9. doi: 10.1056/NEJMoa1410649. N Engl J Med. 2015. PMID: 26244306 Free PMC article. Clinical Trial.
861 results